Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2010

01-12-2010 | Original Article

Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?

Authors: William D. Chey, Reema R. Mody, Esin Izat

Published in: Digestive Diseases and Sciences | Issue 12/2010

Login to get access

Abstract

Background

Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD).

Aim

The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD.

Methods

Separate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects.

Results

Most respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as “somewhat satisfied” to “completely dissatisfied” with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004).

Conclusions

Approximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.
Footnotes
1
PCP categorization included general practitioners, family practitioners, internal medicine practitioners, and osteopathic practitioners.
 
Literature
1.
go back to reference Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.CrossRefPubMed Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.CrossRefPubMed
2.
go back to reference Armstrong D. Systematic review: persistence and severity in gastroesophageal reflux disease. Aliment Pharmacol Ther. 2008;28:841–853.PubMed Armstrong D. Systematic review: persistence and severity in gastroesophageal reflux disease. Aliment Pharmacol Ther. 2008;28:841–853.PubMed
3.
go back to reference Vakil N. Review article: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;19:1041–1049.CrossRefPubMed Vakil N. Review article: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;19:1041–1049.CrossRefPubMed
4.
go back to reference Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Intery Aging. 2007;2:85–92.CrossRef Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Intery Aging. 2007;2:85–92.CrossRef
5.
6.
go back to reference Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors—a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007;26:1355–1360.CrossRefPubMed Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors—a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007;26:1355–1360.CrossRefPubMed
8.
go back to reference Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract. 2005;18:393–400.CrossRefPubMed Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract. 2005;18:393–400.CrossRefPubMed
9.
go back to reference Bretagne JF, Honnohat C, Richard-Mollard B, Caekkaerts A, Barthelemys P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2006;23:607–616.CrossRefPubMed Bretagne JF, Honnohat C, Richard-Mollard B, Caekkaerts A, Barthelemys P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2006;23:607–616.CrossRefPubMed
10.
go back to reference Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease—an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767–776.CrossRefPubMed Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease—an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767–776.CrossRefPubMed
11.
go back to reference Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA. Relationship between symptom load of gastro-esophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther. 2008;27:960–970.CrossRefPubMed Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA. Relationship between symptom load of gastro-esophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther. 2008;27:960–970.CrossRefPubMed
12.
go back to reference Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag. 2000;7:29–34. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag. 2000;7:29–34.
13.
go back to reference Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004;2:CD003245. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004;2:CD003245.
14.
go back to reference Robinson M, Shaw K. Proton pump inhibitor attitudes and usage: a patient survey. Pharm Ther. 2002;27:202–206. Robinson M, Shaw K. Proton pump inhibitor attitudes and usage: a patient survey. Pharm Ther. 2002;27:202–206.
15.
go back to reference Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267–1272.CrossRefPubMed Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267–1272.CrossRefPubMed
16.
go back to reference Hunt R, Yuan Y, Yaghoobi M. GERD: new strategies and new failures. J Clin Gastroenterol. 2007;41(Supp 2):S72–S80.CrossRef Hunt R, Yuan Y, Yaghoobi M. GERD: new strategies and new failures. J Clin Gastroenterol. 2007;41(Supp 2):S72–S80.CrossRef
17.
go back to reference Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–1402.CrossRefPubMed Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–1402.CrossRefPubMed
18.
go back to reference Rubenstein JH, Nojkov B, Korsnes S, et al. Esophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:443–452.CrossRefPubMed Rubenstein JH, Nojkov B, Korsnes S, et al. Esophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:443–452.CrossRefPubMed
19.
go back to reference Nojkov B, Saad R, Adlis S, Shaw M, Chey WD. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Aliment Pharmacol Ther. 2008;27:473–482.CrossRefPubMed Nojkov B, Saad R, Adlis S, Shaw M, Chey WD. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Aliment Pharmacol Ther. 2008;27:473–482.CrossRefPubMed
Metadata
Title
Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?
Authors
William D. Chey
Reema R. Mody
Esin Izat
Publication date
01-12-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1209-2

Other articles of this Issue 12/2010

Digestive Diseases and Sciences 12/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.